Bevespi Aerosphere approved by the Japanese
19 June 2019 07:00 BST Bevespi Aerosphere approved by the Japanese Ministry of Health, Labourand Welfare for patients with chronic obstructive pulmonary disease First approval of a fixed-dose, long-acting dual bronchodilatorin a pressurised metered-dose inhaler device in Japan AstraZeneca today announced that Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Japan as a fixed-dose, long-acting dual bronchodilator to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD). This is the first approval by the Japanese Ministry